obinutuzumab,ibrutinib,lenalidomide,venetoclax,prednisone
jubilant cadista pharma,roche,abbvie,janssen
['lymsm', 'lymphoma', 'vipor']
 discusses the combination regimen from the vipor study evaluating patients with aggressive lymphomas. #lymsm #ash22 | 
Oncology news and insights from leading researchers and cancer centers.